A phase I/IIA trial by Maude et al.27 exhibits that in R/R B-ALL patients treated with lentivirally transduced CD19-CAR-T cells with CD3ζ and 4-1BB, the CR rate is 90% and the rate of MRD negativity is 73%. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.